Nektar Therapeutics (NKTR) Cash from Financing Activities (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Cash from Financing Activities of $529.5 million for Q1 2026, up 7564885.71% year-over-year from N/an in Q1 2025, and up 1269.37% quarter-over-quarter from $38.7 million in Q4 2025.
Nektar Therapeutics (NKTR) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $529.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 7564885.71% year-over-year to $529.5 million; the TTM figure through Mar 2026 stood at $710.1 million (up 581955.74% YoY), while the FY2025 annual figure was $180.6 million, up 328.71% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $529.5 million, up from $38.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $529.5 million in Q1 2026, with the low at $7000.0 in Q1 2025.
- The 5-year median for Cash from Financing Activities is $157000.0 (2022), against an average of $53.8 million.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 99.98% in 2025, then soared 7564885.71% in 2026.
- Nektar Therapeutics' Cash from Financing Activities stood at $103000.0 in 2022, then tumbled by 88.35% to $12000.0 in 2023, then soared by 591.67% to $83000.0 in 2024, then surged by 46491.57% to $38.7 million in 2025, then soared by 1269.37% to $529.5 million in 2026.
- Business Quant data shows NKTR's Cash from Financing Activities at $529.5 million in Q1 2026, $38.7 million in Q4 2025, and $141.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 529.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 529.55 Mn |
| Mar 31, 2026 | 529.55 Mn |
| Dec 31, 2025 | 38.67 Mn |
| Dec 31, 2025 | 38.67 Mn |
| Sep 30, 2025 | 141.68 Mn |
| Sep 30, 2025 | 141.68 Mn |
| Jun 30, 2025 | 211,000.00 |
| Jun 30, 2025 | 211,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 42.00 Mn |
| Mar 31, 2024 | 42.00 Mn |
| Dec 31, 2023 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |